1. Yang J, Hooper WC, Phillips DJ, Talkington DF. Cytokines in
Mycoplasma pneumoniae infections. Cytokine Growth Factor Rev. 2004; 15:157–168.
2. Waites KB, Talkington DF.
Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev. 2004; 17:697–728.
3. Youn YS, Lee KY.
Mycoplasma pneumoniae pneumonia in children. Korean J Pediatr. 2012; 55:42–47.
4. Akira S. The role of IL-18 in innate immunity. Curr Opin Immunol. 2000; 12:59–63.
5. Dinarello CA. Interleukin-18. Methods. 1999; 19:121–132.
6. Chung HL, Kim SG, Shin IH. The relationship between serum endothelin (ET)-1 and wheezing status in the children with
Mycoplasma pneumoniae pneumonia. Pediatr Allergy Immunol. 2006; 17:285–290.
7. Oishi T, Narita M, Matsui K, Shirai T, Matsuo M, Negishi J, et al. Clinical implications of interleukin-18 levels in pediatric patients with
Mycoplasma pneumoniae pneumonia. J Infect Chemother. 2011; 17:803–806.
8. Inamura N, Miyashita N, Hasegawa S, Kato A, Fukuda Y, Saitoh A, et al. Management of refractory
Mycoplasma pneumoniae pneumonia: utility of measuring serum lactate dehydrogenase level. J Infect Chemother. 2014; 20:270–273.
9. Bonecchi R, Galliera E, Borroni EM, Corsi MM, Locati M, Mantovani A. Chemokines and chemokine receptors: an overview. Front Biosci (Landmark Ed). 2009; 14:540–551.
10. Bradley JS, Byington CL, Shah SS, Alverson B, Carter ER, Harrison C, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis. 2011; 53:e25–76.
11. Haugen J, Chandyo RK, Brokstad KA, Mathisen M, Ulak M, Basnet S, et al. Cytokine concentrations in plasma from children with severe and non-severe community acquired pneumonia. PLoS One. 2015; 10:e0138978.
12. Paats MS, Bergen IM, Hanselaar WE, Groeninx van Zoelen EC, Hoogsteden HC, Hendriks RW, et al. Local and systemic cytokine profiles in nonsevere and severe community-acquired pneumonia. Eur Respir J. 2013; 41:1378–1385.
13. Stuyt RJ, Netea MG, Verschueren I, Fantuzzi G, Dinarello CA, Van Der Meer JW, et al. Role of interleukin-18 in host defense against disseminated
Candida albicans infection. Infect Immun. 2002; 70:3284–3286.
14. Lauw FN, Branger J, Florquin S, Speelman P, van Deventer SJ, Akira S, et al. IL-18 improves the early antimicrobial host response to pneumococcal pneumonia. J Immunol. 2002; 168:372–378.
15. Narita M, Tanaka H, Abe S, Yamada S, Kubota M, Togashi T. Close association between pulmonary disease manifestation in
Mycoplasma pneumoniae infection and enhanced local production of interleukin-18 in the lung, independent of gamma interferon. Clin Diagn Lab Immunol. 2000; 7:909–914.
16. Tanaka H, Narita M, Teramoto S, Saikai T, Oashi K, Igarashi T, et al. Role of interleukin-18 and T-helper type 1 cytokines in the development of
Mycoplasma pneumoniae pneumonia in adults. Chest. 2002; 121:1493–1497.
17. Narita M, Tanaka H, Yamada S, Abe S, Ariga T, Sakiyama Y. Significant role of interleukin-8 in pathogenesis of pulmonary disease due to
Mycoplasma pneumoniae infection. Clin Diagn Lab Immunol. 2001; 8:1028–1030.
18. Chmura K, Bai X, Nakamura M, Kandasamy P, McGibney M, Kuronuma K, et al. Induction of IL-8 by Mycoplasma pneumoniae membrane in BEAS-2B cells. Am J Physiol Lung Cell Mol Physiol. 2008; 295:L220–30.
19. Miyashita N, Kawai Y, Inamura N, Tanaka T, Akaike H, Teranishi H, et al. Setting a standard for the initiation of steroid therapy in refractory or severe
Mycoplasma pneumoniae pneumonia in adolescents and adults. J Infect Chemother. 2015; 21:153–160.
20. Wang M, Wang Y, Yan Y, Zhu C, Huang L, Shao X, et al. Clinical and laboratory profiles of refractory
Mycoplasma pneumoniae pneumonia in children. Int J Infect Dis. 2014; 29:18–23.
21. Zhang Y, Zhou Y, Li S, Yang D, Wu X, Chen Z. The clinical characteristics and predictors of refractory Mycoplasma pneumoniae pneumonia in children. PLoS One. 2016; 11:e0156465.
22. Matsuda K, Narita M, Sera N, Maeda E, Yoshitomi H, Ohya H, et al. Gene and cytokine profile analysis of macrolide-resistant
Mycoplasma pneumoniae infection in Fukuoka, Japan. BMC Infect Dis. 2013; 13:591.
23. Yang EA, Lee KY. Additional corticosteroids or alternative antibiotics for the treatment of macrolide-resistant
Mycoplasma pneumoniae pneumonia. Korean J Pediatr. 2017; 60:245–247.
24. Lu A, Wang C, Zhang X, Wang L, Qian L. Lactate dehydrogenase as a biomarker for prediction of refractory
Mycoplasma pneumoniae pneumonia in children. Respir Care. 2015; 60:1469–1475.